Elelyso (taliglucerase) may be a semisynthetic sort of an catalyst that happens naturally within the body. it’s used as an catalyst replacement in individuals with sort I Gaucher unwellness.

Gaucher unwellness may be a genetic condition within which the body lacks the catalyst required to interrupt downsure fatty materials (lipids). Lipids will build up within the body, inflicting symptoms like simple bruising or hurt, weakness, anemia, bone or joint pain, enlarged liver or spleen, or weakened bones that square measure simplybroken.

Elelyso might improve the condition of the liver, spleen, bones, and blood cells in individuals with sort I Gaucherunwellness. However, Elelyso isn’t a cure for this condition.

Submit your review
1
2
3
4
5
Submit
     
Cancel

Create your own review

Average rating:  
 0 reviews
  • Elelyso
  • Get emergency medical help if you have any of these signs of an allergic reaction to Elelyso: hives; difficult breathing; blue lips or fingernails; swelling of your face, lips, tongue, or throat.

    Some people receiving a Elelyso injection have had a reaction when the medicine was injected, or up to 3 hours later. Tell your caregivers right away if you have:

    dizziness, anxiety, weakness, tired feeling;
    sudden headache, or light-headed feeling (like you might pass out);
    flushing (warmth, redness, or tingly feeling);
    fast or uneven heartbeats, chest pain or tightness, wheezing;
    nausea, vomiting; or
    red skin rash.
    Common Elelyso side effects may include:

    headache;
    rash, itching, warmth or tingly feeling;
    dizziness or tired feeling;
    nausea, stomach pain, vomiting; or
    joint pain, back pain, pain in your arms or legs.
  • Usual Adult Dose of Elelyso for Gaucher Disease: Therapy-naive patients: 60 units/kg via IV infusion (administered over 60 to 120 minutes) every other week Patients switching from imiglucerase: -Patients currently being treated with imiglucerase for type 1 Gaucher disease can be switched to this drug. -Patients previously receiving a stable dose of imiglucerase should begin this drug at that same dose when they switch from imiglucerase to taliglucerase alfa. -Dose adjustments can be made based on achievement and maintenance of each patient's therapeutic goals. -A clinical study evaluated doses ranging from 9.5 to 60 units/kg IV every other week. Use: For long-term enzyme replacement therapy (ERT) for patients with confirmed diagnosis of type 1 Gaucher disease Usual Pediatric Dose of Elelyso for Gaucher Disease: 4 years or older: Therapy-naive patients: 60 units/kg via IV infusion (administered over 60 to 120 minutes) every other week Patients switching from imiglucerase: -Patients currently being treated with imiglucerase for type 1 Gaucher disease can be switched to this drug. -Patients previously receiving a stable dose of imiglucerase should begin this drug at that same dose when they switch from imiglucerase to taliglucerase alfa. -Dose adjustments can be made based on achievement and maintenance of each patient's therapeutic goals. -A clinical study evaluated doses ranging from 9.5 to 60 units/kg IV every other week. Use: For long-term enzyme ERT for patients with confirmed diagnosis of type 1 Gaucher disease